Business, energy, technology, markets and global industry news from Business News Today

QIAGEN N.V.

PharmaDeviceNews QIAGEN N.V.
Medical Devices & Diagnostics

EQT offers QIAGEN shareholders a 40% premium, but can its €10.8bn diagnostics bet unlock faster growth?

EQT agrees a €10.8 billion takeover of QIAGEN at €46.50 per share. Diagnostics growth, financing and shareholder approval remain key.

Read More
Molecular diagnostic testing moves into focus as QIAGEN highlights its FDA-cleared QIAstat-Dx Gastrointestinal Panel 2 amid rising U.S. Cyclospora cases. Representative image.
Medical Devices & Diagnostics

How QIAGEN’s FDA-cleared QIAstat-Dx test supports the Cyclospora outbreak response

QIAGEN highlights its FDA-cleared QIAstat-Dx panel as U.S. Cyclospora cases rise, while research tools support outbreak tracing.

Read More
QIAGEN wins FDA clearance for gastrointestinal panels on QIAstat-Dx Rise as syndromic testing platforms expand in U.S. labs
Medical Devices & Diagnostics

How QIAGEN’s QIAstat-Dx Rise GI panel clearance could reshape multiplex pathogen testing in clinical labs

QIAGEN wins FDA clearance for GI panels on QIAstat-Dx Rise. Discover what this means for syndromic testing platforms and molecular diagnostics adoption.

Read More